Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.

Published on May 1, 2020in Clinical & Translational Oncology2.737
· DOI :10.1007/S12094-019-02188-7
M. De Santis13
Estimated H-index: 13
M.C. De Santis1
Estimated H-index: 1
+ 13 AuthorsS. Di Cosimo15
Estimated H-index: 15
Background Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship between tumor size, hormone receptor and HER2 status, Ki67 and age with axillary lymph node metastases (ALNM) in early-BC patients.
📖 Papers frequently viewed together
23 Citations
5 Authors (Lingquan Kong, ..., Kai-nan Wu)
#1Lin-Wei Guo (Fudan University)H-Index: 2
#2Lin-Miao Jiang (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Xin Hu (Fudan University)H-Index: 7
view all 9 authors...
Purpose: TNBC is generally more aggressive than other BC subtypes and has limited therapeutic options. We aimed to construct comprehensive and reliable nomograms to predict the OS and BCSS of TNBC patients to offer clinicians therapeutic guidance for improving the prognosis of TNBC patients. Patients and methods: We used the SEER 19 Cancer Registry to identify 21,419 eligible TNBC patients diagnosed from January 1, 2010 to December 31, 2015, and divided the database randomly into a training coho...
9 CitationsSource
#1Ning Liu (Tianjin Medical University)H-Index: 5
#2Zhigang YangH-Index: 1
Last. Yun Niu (TMUCIH: Tianjin Medical University Cancer Institute and Hospital)H-Index: 7
view all 4 authors...
// Ning Liu 1 , Zhigang Yang 2 , Xiaozhen Liu 3 and Yun Niu 3 1 Department of Pathology, Bao Di Hospital, Bao Di Clinical College of Tianjin Medical University, Tianjin, China 2 Tianjin Baodi Hospital of Traditional Chinese Medicine, Tianjin, China 3 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, M...
13 CitationsSource
#2Wolfram MalterH-Index: 7
Last. Verena KirnH-Index: 6
view all 7 authors...
Abstract Objectives Since the introduction of the sentinel node technique for breast cancer in the 1990s patient's morbidity was reduced. Tracer uptake is known to be dependent from lymph node integrity and activity of macrophages. The aim of this study was to assess whether radioactivity of the tracer can predict sentinel lymph node metastases. Furthermore, a potential association with Ki-67 index was examined. Non-invasive prediction of lymph node metastases could lead to a further decrease of...
4 CitationsSource
#1Roopa Lakhanpal (Canberra Hospital)H-Index: 3
#2Ivana Sestak (QMUL: Queen Mary University of London)H-Index: 32
Last. Angela Rezo (Canberra Hospital)H-Index: 5
view all 9 authors...
Abstract Purpose Immunohistochemical 4 (IHC4) score plus Clinical Treatment Score (CTS) is an inexpensive tool predicting risk of distant recurrence in women with early breast cancer (EBC). IHC4 score is based on ER, PR, HER2 and Ki67 index. This study explores the role of the combined score (IHC4 + CTS) in predicting risk of locoregional recurrence (LRR) in women with EBC who had breast conservation surgery (BCS) without adjuvant radiotherapy (study group). The secondary objective was to evalua...
12 CitationsSource
#1Lori M. van Roozendaal (UM: Maastricht University)H-Index: 5
#2Leonie H. M. Smit (UM: Maastricht University)H-Index: 2
Last. Marjolein L. Smidt (UM: Maastricht University)H-Index: 25
view all 9 authors...
Triple-negative breast cancer is associated with early recurrence and low survival rates. Several trials investigate the safety of a more conservative approach of axillary treatment in clinically T1-2N0 breast cancer. Triple-negative breast cancer comprises only 15 % of newly diagnosed breast cancers, which might result in insufficient power for representative results for this subgroup. We aimed to provide a nationwide overview on the occurrence of (regional) recurrences in triple-negative breas...
27 CitationsSource
#1Carsten Denkert (Charité)H-Index: 82
#2Jan Budczies (Charité)H-Index: 42
Last. Frederick Klauschen (Charité)H-Index: 41
view all 6 authors...
Abstract Increased proliferation is a hallmark of malignant tumors. The proliferation marker Ki67 has been investigated as a breast cancer biomarker, but despite 32 years of research the best cutpoints and the best methods for determination are still under debate. This review is based on an overview on the efforts to standardize Ki67 and to optimize its performance that was presented at the St. Gallen oncology conference 2015. The clinical validity of Ki67 as a prognostic marker as well as a pre...
78 CitationsSource
#1Paolo BailiH-Index: 20
#2Michele TorresaniH-Index: 4
Last. Milena SantH-Index: 48
view all 16 authors...
In clinical research, many potentially useful variables are available via the routine activity of cancer center-based clinical registries (CCCR). We present the experience of the breast cancer clinical registry at Fondazione IRCCS “Istituto Nazionale dei Tumori” to give an example of how a CCCR can be planned, implemented, and used. Five criteria were taken into consideration while planning our CCCR: (a) available clinical and administrative databases ought to be exploited to the maximum extent;...
8 CitationsSource
#1Patrick Maisonneuve (IEO: European Institute of Oncology)H-Index: 109
#2Davide Disalvatore (IEO: European Institute of Oncology)H-Index: 15
Last. Aron Goldhirsch (IEO: European Institute of Oncology)H-Index: 84
view all 13 authors...
Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A–like breast cancer from luminal B–like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choic...
100 CitationsSource
#1Nirmala Pathmanathan (USYD: University of Sydney)H-Index: 11
Last. John Boyages (Macquarie University)H-Index: 31
view all 9 authors...
Aim To evaluate the utility of Ki67 as a prognostic marker in a series of patients with node-negative breast cancer untreated with adjuvant systemic therapy. Methods The cohort consisted of 203 cases treated with breast conserving surgery and radiation only; median follow-up was 183 months (range 156–277 months). An immunohistochemical panel of oestrogen receptor (ER), progesterone receptor (PR), cytokeratin (CK)5/6 and Ki67 and human epidermal growth factor 2 in situ hybridization (HER2-ISH) wa...
26 CitationsSource
#1Colin A. Purdie (Dund.: University of Dundee)H-Index: 37
#2Philip R. Quinlan (Dund.: University of Dundee)H-Index: 19
Last. Alastair ThompsonH-Index: 16
view all 7 authors...
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study
87 CitationsSource
Cited By0